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Background: A new subcutaneous specific immunotherapy (SCIT) product adsorbed on aluminium hydroxide has
been developed with a short and simplified up-dosing phase, containing a biologically standardized allergen pollen
extract from Olea europaea.
Objective: To assess the tolerability profile of the updosing phase and its immunological effect, in terms of specific
IgG4 and IgE levels and immediate skin reactivity.
Material and methods: The study was an exploratory, multi-centre, open-label, single-arm, phase II/III clinical trial.
Adults with a clinical history of allergic rhinoconjunctivitis with/without asthma due to sensitization to olive pollen
were selected. Five up-dosing doses (300, 600, 3000, 6000 and 15000SQ+) were administered at weekly intervals,
followed by a maintenance dose (15000SQ+) after 2 weeks. Adverse events were collected during the 30 min
observation period after injections, after a telephone contact 2 days after each visit, and after reviewing the subjects’
diary. IgG4 and IgE levels and immediate skin reactivity were evaluated at the beginning and at the end of the trial.
Results: Ninety-three subjects were included in the trial (mean age, 35.7 ± 10.3 years; women, 66.7 %). A total of 95
adverse drug reactions, all mild in intensity and non-serious, were reported during the trial: 85 local in 34.4 % subjects,
9 systemic in 4.3 % subjects and one non-specific (grade 0). Within 6 weeks, significant changes in IgG4 and IgE levels
and in immediate skin reactivity to Olea europaea were accomplished.
Conclusion: This new SCIT derived from pollen of Olea europaea presented a good tolerability profile and induced
significant immunological responses already after a 6 week treatment. However, the non-controlled design may limit
the interpretation of these results.
Trial registration: EudraCT no: 2011-004852-20; ClinicalTrials.gov Identifier: NCT01674595.
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Allergic rhinoconjunctivitis and asthma are, frequently,
concurrent disorders [1, 2], which has led to the notion
that these two conditions are different aspects of the
same disease [3, 4]. Results from the ONEAIR study, a
prospective observational study conducted between 2004
and 2005 with 942 subjects from Spain, reinforced this
idea, highlighting that almost 90 % of subjects suffering
from asthma presented concomitant allergic rhinitis [5].
The ability of olive pollen (Olea europaea) to induce
notorious symptoms of rhinitis and/or asthma in ex-
posed populations through an IgE-mediated mechanism
is amply documented in the Mediterranean areas [6–12].
A study conducted in 4000 allergic subjects from all over
Spain showed that 47 % of subjects suffering from allergic
rhinoconjunctivitis and 51 % of asthmatics were sensitized
to Olea europaea, which emphasizes the importance of
olive pollen allergen in Spain [13].
Available treatment options in respiratory allergic condi-
tions include allergen avoidance, symptomatic treatment
and etiologic treatment. Olive pollen allergen avoidance is
hardly applicable since only a limited reduction in expos-
ure can be achieved by modifying life habits. Symptomatic
treatment offers short-term symptomatic relief, but does
not offer long-term benefit, as the natural course of the
disease is not affected. Etiologic treatment with allergen-
specific immunotherapy (AIT) has proven to be the most
effective treatment option for allergic diseases. AIT in-
volves administering specific allergens to patients suffering
from IgE-mediated allergic diseases in order to ameliorate
symptoms, induce sustained and long-term immuno-
logical tolerance to the causative allergen, and potentially
alter the natural course of the disease [14–16].
The subcutaneous route for the administration of AIT
products has been proven to be clinically efficacious and
well-tolerated in a number of studies [17–19]. The
standard schedule for the subcutaneous immunotherapy
(SCIT) starts with an induction period or up-dosing
phase, involving increasing weekly doses over a number
of consecutive weeks (12–14 weeks) until the mainten-
ance dose is reached; however, there has been growing
interest in reducing the initiation period to facilitate AIT
compliance [20]. A new SCIT product containing aller-
gen extract of Olea europaea (AVANZ® Olive) has been
developed based on previous SCIT products.
Therefore, all the above considerations prompted us to
assess the tolerability and the immunological effect of
the up-dosing phase of this new SCIT containing aller-
gen extract derived from olive pollen.
Methods
Study design
This was an open-label, single-arm, phase II/III multi-
center clinical trial conducted at 10 sites in Spain, whereolive pollen is an important cause of rhinitis and/or bron-
chial asthma. The study was approved by the applicable
ethics committees and by the Spanish Drug Agency, and
written informed consent was obtained from all subjects
before their inclusion in the study. The trial was con-
ducted in accordance with the Declaration of Helsinki [21]
and in compliance with the Good Clinical Practice Guide-
lines [22]. The trial was registered on ClinicalTrials.gov
under identification number NCT01674595.
Study population
The study population comprised adult subjects aged 18 to
65 years with a clinical history of olive pollen-induced
allergic rhinoconjunctivitis and/or asthma at least 1 year
prior to trial entry, a positive skin prick test (SPT) re-
sponse to Olea europaea (wheal diameter ≥ 3 mm), and a
positive specific IgE against olive pollen (≥ IgE class 2; ≥
0.70 KU/L) documented within the last 5 years. Subjects
with forced expiratory volume in 1 s (FEV1) < 70 % of
the predicted value at screening, uncontrolled or severe
asthma, and a history of severe asthma exacerbation [23]
were not included in the study. Subjects were also ex-
cluded if they had had an emergency room visit/admission
because of asthma within the previous 12 months, a
history of anaphylactic shock due to food, insect venom,
exercise or drug, or severe and recurrent angioedema, or
previous treatment with olive AIT within the previous
5 years or other concomitant AIT.
Interventions
The trial was initiated after the olive pollen season of
2012. AVANZ® Olive injections were given by trained
nurses and under supervision of expert allergists in Im-
munotherapy Units following national and international
recommendations [24].
Subjects were administered 5 weekly subcutaneous
up-dosing injections (300 SQ+, 600 SQ+, 3000 SQ+,
6000 SQ+ and 15,000 SQ+), followed by the mainten-
ance injection (15,000 SQ) 2 weeks after, as part of the
short course of SCIT (6 weeks). Two days after each
visit, subjects were contacted by telephone to record any
adverse event.
Evaluations
Tolerability (primary endpoint) was assessed throughout
the study as the incidence of adverse drug reactions
(ADR) recorded during the 30 min waiting period after
each injection, through phone calls 2 days after each
injection and by reviewing the patients’ diaries issued to
record any untoward experience. ADRs were defined as
all noxious and unintended responses to any dose of the
Investigational Medicinal Product (IMP) administered,
and were classified as immediate (within 30 min after
the injection) or delayed (>30 min after the injection).
Fig. 1 Study design flow chart
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occurring at the injection site), or systemic (SR, gene-
ralised signs/symptoms occurring away from the injec-
tion site). All LRs were recorded, regardless of size,
including (diffuse) swelling, redness (erythema), pain,
itching (pruritus) or injection site reaction (if two or
more local symptoms occurred simultaneously); SRs
were graded by the investigator according to the Euro-
pean Academy of Allergy and Clinical Immunology
(EAACI) guidelines [24]. Additionally, all AEs where
coded according to the Medical Dictionary for regulatory
Activities (MedDRA).
At SCIT initiation (visit 1) and 6 weeks after the begin-
ning of SCIT (visit 6), SPT to 5-fold concentrations of
Olea europaea allergen extracts (12, 60 and 300 μg/ml
Ole e 1) was performed and blood samples were taken
for immunological assessments (secondary endpoint),
including Olea europaea-specific IgG4 and IgE levels by
ImmunoCAP (Phadia AB Uppsala). Changes in immedi-
ate skin response to Olea europaea were analyzed using
the parallel line assay (PLA) [25], expressed as the cuta-
neous tolerance index (CTI), which indicates the differ-
ence in allergen concentration needed to elicit the same
response.
Statistical considerations
Statistical analyses were performed on the full ana-
lysis set of subjects, using the available data without
imputation of missing values. The tolerability profile
was determined using descriptive analyses. Changes in
specific IgG4 and IgE levels between visit 1 and visit
6 were performed using Student’s t-test for paired
samples. All statistical analyses were performed using
the Statistical Package for the Social Sciences (SPSS)
version 17.
Results
From September 2012 to April 2013, a total of 96 sub-
jects were enrolled in the trial; as three subjects failed
screening, 93 subjects were administered the IMP. Of
these, three subjects discontinued before completing the
study treatment (Fig. 1). The subjects’ baseline charac-
teristics are presented in Table 1.
Tolerability
Thirty-four subjects (36.6 %) of IMP-exposed partici-
pants reported a total of 95 ADRs during the trial
(Table 2). All ADRs were mild in intensity and non-
serious, and all participants recovered fully. In one sub-
ject dose adjustment due to ADRs was done. A total of
85 local ADRs were reported by 32 (34.4 %) subjects
without leading to changes in the administration sched-
ule. Nine systemic ADRs were reported in 4 (4.3 %) sub-
jects, all mild, non-serious, delayed and EAACI grade I.One subject experienced 4 SRs with different doses,
two subjects two SRs each with the same dose and one
subject only one SR. All dose concentrations elicited
SRs and no risks were associated with a particular dose.
SRs consisted in asthma symptoms and oticus and
pharyngeal pruritus. Table 3 shows the nature of local
and SRs by MedDRA System Organ Class (SOC) and
Preferred Term (PT). One subject reported a non-
specific (grade 0) ADR. No subjects required treatment
with adrenaline and no safety concerns were raised for
vital signs. IMP-unrelated AEs accounted for 84 events
in 34 subjects.
Immunological effect
A statistically significant increase of IgG4 and IgE levels
to Olea europaea was observed from visit 1 to visit 6
(Table 4). Furthermore, within 6 weeks of treatment with
Olea europaea SCIT, a significant reduction in immedi-
ate skin reactivity was observed with a CTI of 2.34 (95 %
confidence interval (CI), 1.72 - 3.19). Changes in imme-
diate skin reactivity over time are shown in Fig. 2.
Discussion
Olive pollen is one of the most important causes of
inhalant allergy in the Mediterranean countries [26] and
is becoming the main disease-eliciting pollen in some
provinces of Southern Spain (i.e. Córdoba, Jaén). The
aim of this study was to determine the tolerability profile
of the up-dosing phase of the new SCIT with Olea
europaea allergen extract, measured as the incidence of
Table 1 Subjects’ baseline characteristics (N = 93)
Baseline characteristics Value
Age (years), mean ± SD 35.7 ± 10.3
Women, n (%) 62 (66.7)




Main concomitant illness, n (%):
Asthma 64 (68.8)
Rhinoconjunctivitis 93 (100)
BMI (kg/m2), mean ± SD 25.9 ± 4.2
Vital signs, mean ± SD:
Systolic blood pressure (mmHg) 120.2 ± 13.7
Diastolic blood pressure (mmHg) 73.7 ± 8.8
Heart rate (bpm) 74.2 ± 8.1
Smoking habits, n (%):
Non-smoker 72 (77.4)
Smoker 14 (15.1)
Previous smoker 7 (7.5)






BMI body mass index, bpm beats per minute, n (%) number and percentage of
subjects, SD standard deviation
Table 2 Summary of adverse drug reactions
e n (%)
IMP-related adverse events 95 34 (36.6)
Severity
Mild 95 34 (36.6)
Moderate 0 0
Severe 0 0
Change in treatment schedule
None 93 33 (35.5)
Temporarily interrupted 2 1 (1.1)
Discontinued 0 0
Prior to first intake 0 0
Classification according to EAACI guideline
LR 85 32 (34.4)
SR 9 4 (4.3)
Grade 0/Nonspecific 1 1 (1.1)
Dose
300 SQ+ 16 13 (14.0)
600 SQ+ 11 11 (11.8)
3,000 SQ+ 24 22 (23.7)
6,000 SQ+ 17 17 (18.3)
15,000 SQ+ 26 15 (16.1)
Dose unknown 1 1 (1.1)
ADR adverse drug reaction, e number of events, EAACI European Academy of
Allergy and Clinical Immunology, n (%) number and percentage of subjects,
LR local reactions, SQ+ standardized quality units, SR systemic reactions
Table 3 Nature of adverse drugs reactions
System organ class and preferred term e n (%)
Ear and labyrinth disorders
Ear pruritus 1 1 (1.1)
General disorders and administration site conditions
Asthenia* 1 1 (1.1)
Chest discomfort 1 1 (1.1)
Injection site erythema 1 1 (1.1)
Injection site pain 3 3 (3.2)
Injection site pruritus 25 12 (12.9)
Injection site reaction 52 22 (23.7)
Injection site swelling 4 3 (3.2)
Respiratory, thoracic and mediastinal disorders
Asthma 4 1 (1.1)
Throat irritation 3 3 (3.2)
e, number of events; n (%), number and percentage of subjects
* EAACI Grade 0 (No symptoms or nonspecific symptoms of systemic reaction)
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so, subjected to a certain degree of bias which may limit
the interpretation of the results. However, regarding
tolerability, the frequency of ADRs can be considered
conservative, because all AEs with a temporary relation
to the treatment with no other attributable cause have
been related to the studied treatment. With regards to
the immunological endpoints, the specificity of the im-
munological evaluations does not require a control
group as it would be the case of a clinically-related
endpoint.
The nature of the ADRs observed during treatment
with this new SCIT was as expected. Over one-third of
the study population suffered at least one ADR. All
ADRs were mild in intensity, occurred at all dosing
steps, most were related to the injection site and all par-
ticipants achieved full recovery. Only one subject inter-
rupted temporally the dosing schedule.
We have followed the current guidelines of the Euro-
pean Medicines Agency (EMA) on clinical development
of AIT [27] and all AEs have been coded with MedDRA.Consequently, all local ADRs have been reported, inde-
pendently of their size. These two factors, together with
the way AEs were registered, proactively with a phone
call 2 days after each injection and with a subject diary,
may explain the apparently higher rate of ADRs in this
Table 4 Levels of IgG4 and IgE to Olea europaea
n Visit 1 (mean ± SD) Visit 6 (mean ± SD) Effect size p-value*
IgG4 (mgA/l) 90 0.34 ± 0.37 0.97 ± 1.13 0.64 <0.001
IgE (KU/l) 90 34.07 ± 36.09 47.50 ± 47.82 13.43 <0.001
n number of subjects with valid data in visit 1 and visit 6, SD standard deviation
*p-values correspond to paired Student’s t-test
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between trials due to these differences in the safety
reporting methodology, the pattern of the ADRs ob-
served in this trial seems to be in line with previous ex-
perience and with what has been observed in previous
clinical trials with other AIT products [28, 29].
A similar clinical trial led by Tabar AI [30], conducted
with 102 subjects with the same SCIT formulation contain-
ing a house dust mite (Dermatophagoides mix)-derived al-
lergen extract, showed similar results in terms of number
and nature of the ADRs, with 4.9 % of the study population
reporting mild, grade I SRs and a similar rate of LRs. In a
randomised open controlled study of SCIT with a similar
Olea europaea standardised allergen extract quantified in
mass units performed with a conventional up-dosing
schedule in a province of the Southern region of Spain
(Jaén), where pollen counts may reach 7000 grains/m3,
Gonzalez et al. [28] reported similar results with a rate of
SRs of 8.7 %, with 3 mild and 1 moderate reactions.
One of the secondary endpoints of our study was to
determine the immunological effect of this new SCIT
formulation by measuring the specific levels of IgE and
IgG4. Specific immunoglobulin levels are essential to
establish the immune response of allergen immuno-
therapy, as the induction of IgG4 potentially blocks the
proportion of IgE-facilitated antigen to T cells and eosin-
ophils, resulting in a reduction of IgE production and
the inflammatory response [29]. As might be expected,
this new SCIT with olive pollen allergen extract induced
immunological responses reflected as statisticallyFig. 2 Changes in immediate skin reactivity by parallel line assay.
Subjects were prick-tested with an Olea europaea pollen allergen
extract containing 12, 60 and 300 μg/ml Ole e 1 before (V1) and
after (V6) 6 week treatment. The reduction of skin reactivity was
assessed by parallel line assay. CTI, Cutaneous Tolerance Indexsignificant increments of specific levels of IgE and IgG4
within 6 weeks of therapy. AIT often induces a short-
term increase in IgE levels followed by a long-term de-
crease and a rapid increase in IgG4, [19, 28, 31, 32]
which can block the binding of IgE to allergens and B
cells. The induction of T-regulatory cells (Treg) by AIT
is central to the suppression of the allergic reaction:
Treg produce IL-10 which is able to suppress IgE pro-
duction by B cells and to induce IgG4 [33].
Several studies have evaluated the effect of SCIT on
cutaneous reactivity to the causative allergen, showing
continuous reduction in cutaneous response, which in
some studies has been seen to correlate with clinical
efficacy [34]. In our study, we achieved progressive re-
duction in immediate skin reactivity to the different
concentrations of olive allergen extract, expressed as the
CTI, i.e. the factor by which the extract concentration
has to be multiplied to obtain the same response as in
the beginning in a linear dose–response relationship.
Recently, Tabar AI et al. [30] reported similar results,
achieving a CTI of 1.44 (95 % CI, 1.04 - 1.98) after
6 weeks of immunotherapy. Likewise, clinical trials led
by Martínez-Cocera [35] and Vidal [36] showed similar
reductions in skin reactivity after a short course of AIT
with allergen extract derived from Phleum pratense and
house dust mites, respectively.
Conclusion
The results of this phase II/III clinical trial show that
immunotherapy with a biologically standardized allergen
extract derived from Olea europaea in a 6 week schedule
has a good tolerability profile and induces significant im-
munological responses in subjects suffering from allergic
rhinoconjunctivitis and/or asthma due to sensitization to
olive pollen.
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